Colorectal Cancer Metastasis (Volume II)
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Pathophysiology".
Deadline for manuscript submissions: 10 November 2024 | Viewed by 128
Special Issue Editors
Interests: colorectal cancer; breast cancer; complementary and alternative medicine
Special Issues, Collections and Topics in MDPI journals
Interests: abdominal cancers; colorectal cancer; immunotherapy; genomic landscape; neuroendocrine tumors
Special Issues, Collections and Topics in MDPI journals
Interests: colorectal cancer; genetics
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This collection is the second edition of the previous one, “Colorectal Cancer Metastasis”: https://www.mdpi.com/journal/cancers/special_issues/3C
The primary objective of the inaugural edition of this Special Issue was to stimulate interdisciplinary research on the intricate genetics of metastatic colorectal cancer (mCRC), providing insights into its prognosis, predictive markers, and cancer plasticity.
In contrast, the second edition is geared towards furthering our comprehension of mCRC to facilitate precision medicine and treatment design. Over recent years, substantial strides have been made in the management of mCRC. In addition to traditional chemotherapy agents, such as fluorouracil, irinotecan, and oxaliplatin, a novel class of drugs has emerged, encompassing biologically targeted agents like cetuximab, panitumumab, aflibercept, regorafenib, and encorafenib, alongside innovative “non-selective” mechanism-of-action oral medications like capecitabine and trifluridine/tipiracil. Nonetheless, it is important to note that immunotherapy remains applicable to only a small subset of patients with microsatellite instability, constituting less than 5% of cases.
While numerous therapeutic options remain under investigation, lacking widespread consensus regarding their effectiveness or regulatory approval, it is evident that mCRC has not experienced the same level of progress in systemic therapy management observed in other cancer types, such as lung and breast cancer. This disparity underscores the intricacy of the disease, marked by biological diversity and a relatively constrained understanding of its molecular drivers.
Acknowledging the pressing need for further progress in the field, this second edition of the Special Issue “Colorectal Cancer Metastasis” aspires to contribute to the existing body of knowledge by promoting research that can potentially lead to the discovery of new treatments and therapeutic strategies (including treatment sequences, real-world clinical case series, and patient selection criteria) for mCRC. We invite submissions of scientific articles to facilitate more profound insights into this challenging condition.
Articles that solely comprise bioinformatics or computational analyses of publicly available databases will not be considered for acceptance. We welcome submissions of analyses and studies that originate from real-world clinical practice and independent patient cohorts. Additionally, we highly value and encourage the submission of review articles.
Dr. Massimiliano Berretta
Dr. Alessandro Ottaiano
Dr. Mariachiara Santorsola
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- colorectal cancer
- genetics
- epigenetics
- metastases
- prognosis
- cancer evolution
- precision medicine
